key: cord-0928073-56yazhze authors: Saied, AbdulRahman A.; Metwally, Asmaa A.; Dhama, Kuldeep title: Our children are at risk of COVID-19- associated rhino-orbito-cerebral mucormycosis (ROCM) date: 2021-11-16 journal: Ann Med Surg (Lond) DOI: 10.1016/j.amsu.2021.103058 sha: 08e3d91da265876f63c533b003bdb365b0e7eab6 doc_id: 928073 cord_uid: 56yazhze nan multisystem inflammatory syndrome (MIS-C) [14] [15] [16] [17] [18] . There are current endeavors for 27 developing an effective vaccine and testing the current available vaccines for their suitability 28 in kids to protect them against SARS-CoV-2 and its newly emerged variants of concern, such 29 as delta variant (called Indian variant) and others are surging, characterized by higher 30 transmissibility, virulence and causing vaccine break-through events [19] [20] [21] . The 31 extraordinary worldwide surge in instances of COVID-19 related mucormycosis drove medical 32 health to the edge even before the assault of the ongoing COVID-19 pandemic could settle. Alongside the SARS-CoV-2 lethal impact and the diabetogenic condition [22, 23] facilitates Mucorales spores to germinate in patients with COVID-19. This fungus thrives in an 37 environment of elevated glucose and acid pH, as it has an active ketone-reductase system [24] . The high fungal spore load in the Indian environment, besides the immunosuppression induced 39 by COVID-19 itself, systemic steroids and anti-Interleukin-6 agents (e.g, tocilizumab), 40 provides a suitable environment for invasive fungal diseases in our children as susceptible hosts 41 [12] . Rhino-orbital cerebral mucormycosis (ROCM) is a rare but rapidly progressing 43 disease that can result in death if not recognized and treated timely and aggressively, and this 44 fungal disease spread like an epidemic within in the COVID-19 pandemic [25] . Uncontrolled 45 diabetes is just a predisposing factor in 15% of pediatric patients. Early diagnosis based on 46 clinical symptoms and biopsy is highly suggested to avoid and minimize fatality rates from this 47 serious disease [13] . In India, an alarming rise in ROCM in post-COVID cases has been 48 documented in adult patients with uncontrolled diabetes. Diwakar J, et al, [12] have also and subsequent threats of mucormycosis in affected patients [34] . Rhino-orbital Cerebral Mucormycosis, StatPearls [Internet COVID-19 outbreak: A fatal addition to the pandemic spectrum COVID-19-Associated Mucormycosis (CAM): An updated evidence mapping COVID-19, Diabetes and Steroids: The Demonic Trident for 115 Mucormycosis Syndemic in India COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic 121 Challenges to Management Pediatric patients with Type 1 Diabetes Mellitus Rhino-orbital cerebral mucormycosis in a child with type 1 diabetes COVID-19 in Early Life: Infants and Children Are Affected Too multisystem syndrome temporally associated with SARS-CoV-2 Current Insights Into the Pathophysiology of Multisystem 140 Coronavirus Disease 2019 Vaccine in Children Viewpoint of the European Pediatric Societies over 145 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Children 146 Younger Than Age 12 Years Amid Return to School and the Surging Virus Variants Hospital admission and emergency care attendance risk 150 CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort 151 study -2: a systematic review and meta-analysis Mucormycosis in COVID-19: a systematic review 160 Rhino-orbital-cerebral mucormycosis: fungal epidemic 162 Rhino-Orbital Mucormycosis in Patients With COVID-19 Favors Clinical Outcome: A Case 172 Invasive Fungal Infections in Children with 174 Haematological Malignancies: Diagnostic and Therapeutic Challenges for the diagnosis, prevention, and treatment of invasive fungal diseases in 179 paediatric patients with cancer or post-haematopoietic cell transplantation Innovations in COVID-19 testing: the road from pandemic 181 response to control Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal 184 viral shedding Name of the registry: 2. Unique Identifying number or registration ID: 3. Hyperlink to your specific registration The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated. All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.The authors declare that there is no conflict of interests Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.All the authors contributed significantly in this manuscript. AAS conceptualized the manuscript. AAS wrote the first draft with input from AAM, and KD reviewed and updated the manuscript. All authors contributed to revisions and approved the final manuscript.J o u r n a l P r e -p r o o f In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.